跳至主要内容
临床试验/NCT00667901
NCT00667901终止1 期

A Phase 0 Trial of Riluzole in Patients With Resectable Stage III and IV Melanoma

University of Medicine and Dentistry of New Jersey2 个研究点 分布在 1 个国家目标入组 15 人开始时间: 2007年2月最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
终止
入组人数
15
试验地点
2
主要终点
Measurement of the inhibition of components of the Grm1 signaling cascade

研究概览

简要总结

RATIONALE: Riluzole may stop or slow the growth of tumor cells and may be an effective treatment for melanoma.

PURPOSE: This early phase I trial is studying how well riluzole works in treating patients with stage III or stage IV melanoma that can be removed by surgery.

详细描述

OBJECTIVES:

Primary

  • To evaluate the potential effects of glutamate receptor blockade on cellular pathways important in the genesis and progression of melanoma in patients with stage III or IV melanoma undergoing surgical resection.
  • To determine whether treatment with riluzole alters expression of activated PLC and ERK in lysates from tumor tissue biopsies.

Secondary

  • Determine if treatment with riluzole affects the overall metabolic activity of melanoma tumors as measured by pre- and post-treatment PET scanning, pre- and post-treatment tumor mitotic rate evaluation, and pre- and post-treatment immunohistochemical staining for Ki-67.

研究设计

研究类型
Interventional
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Measurement of the inhibition of components of the Grm1 signaling cascade

次要结局

  • Mitoses in nodal metastases and Ki-67 immunostaining (0-3+ scale)

研究者

研究点 (2)

Loading locations...

相似试验